Stoke Therapeutics (NASDAQ:STOK) Insider Sells 4,767 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 4,767 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $152,687.01. Following the completion of the transaction, the insider directly owned 25,655 shares of the company’s stock, valued at approximately $821,729.65. This trade represents a 15.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Barry Ticho also recently made the following trade(s):

• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04.
• On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK traded up $0.01 during trading on Tuesday, reaching $32.14. 574,554 shares of the company were exchanged, compared to its average volume of 816,472. The business’s fifty day simple moving average is $30.81 and its 200-day simple moving average is $32.21. Stoke Therapeutics, Inc. has a 12-month low of $18.00 and a 12-month high of $40.22. The firm has a market capitalization of $2.07 billion, a PE ratio of -9.62 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. On average, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -3.5 EPS for the current fiscal year.

Institutional Trading of Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC purchased a new position in shares of Stoke Therapeutics during the 4th quarter worth $26,000. Quantbot Technologies LP acquired a new position in shares of Stoke Therapeutics during the 2nd quarter valued at about $34,000. KBC Group NV purchased a new stake in shares of Stoke Therapeutics in the first quarter valued at about $36,000. Harbour Investments Inc. increased its position in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the last quarter.

Analyst Ratings Changes

STOK has been the subject of a number of research analyst reports. Wedbush increased their target price on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. The Goldman Sachs Group started coverage on Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 11th. Chardan Capital reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Finally, Canaccord Genuity Group dropped their target price on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $43.00.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.